Insilico Medicine Advances AI-Driven GIPR Antagonist with Strong…

Event summary

Insilico Medicine nominated ISM1354, a next-generation small molecule GIPR antagonist, for obesity and related disorders.
ISM1354 demonstrated 18-fold greater plasma exposure than a clinical-stage benchmark compound and a 45-fold margin of safety.
The company has nominated 10 preclinical candidate compounds in the first 9 months of 2026, bringing the total to 34 since 2021.
Insilico reported $106 million in revenue and $51 million in adjusted net profit for the first half of 2026, marking its first profitable half-year since listing.
The company's disclosed deal value for signed collaborations in 2026 alone has reached approximately $7.3 billion.

The big picture

Insilico Medicine's nomination of ISM1354 underscores the growing importance of AI in drug discovery, particularly in addressing the challenges of obesity and related metabolic disorders. The company's strong financial performance and extensive partnership network highlight its strategic position in the biotechnology sector. As the demand for weight management solutions continues to expand, Insilico's AI-driven approach could set a new standard for developing safer and more effective therapies.

What we're watching

Clinical Validation: Whether ISM1354 can maintain its safety and efficacy profile in GLP toxicology studies and subsequent clinical trials.
Market Expansion: The pace at which Insilico can expand into cardiovascular diseases and other indications related to obesity.
AI Platform Scaling: How Insilico's generative AI platform will drive further innovation and exploration of new modalities.